Holly Price

Holly Price

Auto-generated profile, based on publicly available information

Holly Price

Vision and Eye Research Institute, School of Medicine Anglia Ruskin University Cambridge UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JLJanet L. Leasher
Janet L. Leasher
RBRupert R.A. Bourne
Rupert R.A. Bourne
SFSeth R. Flaxman
Seth R. Flaxman
JJJost B. Jonas
Jost B. Jonas
JKJill Keeffe
Jill Keeffe
OSon behalf of the Vision Loss Expert Group of the Global Burden of Disease Study
on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study
OBJECTIVE: To estimate global and regional trends from 1990 to 2010 of the prevalence and number of persons visually impaired specifically by diabetic retinopathy (DR), as a complication of the precipitous trends in global diabetes, is fundamental for health planning purposes. RESEARCH DESIGN AND METHODS: The meta-analysis of published population studies from 1990 to 2012 for the Global Burden of Disease Study 2010 (GBD) yielded estimated global regional trends in DR among other causes of moderate and severe vision impairment (MSVI; presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60). RESULTS: Globally in 2010, out of overall 32.4 million blind and 191 million visually impaired people, 0.8 million were blind and 3.7 million were visually impaired because of DR, with an alarming increase of 27% and 64%, respectively, spanning the two decades from 1990 to 2010. DR accounted for 2.6% of all blindness in 2010 and 1.9% of all MSVI worldwide, increasing from 2.1% and 1.3%, respectively, in 1990. These figures were lower in regions with younger populations (4%). CONCLUSIONS: The number of persons with visual impairment due to DR worldwide is rising and represents an increasing proportion of all blindness/MSVI causes. Age-standardized prevalence of DR-related blindness/MSVI was higher in sub-Saharan Africa and South Asia. One out of 39 blind people had blindness due to DR, and 1 out of 52 visually impaired people had visual impairment due to DR.

25 February 2014 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
KNKovin Naidoo
Kovin Naidoo
SGStephen Gichuhi
Stephen Gichuhi
MBMaria-Gloria Basanez
Maria-Gloria Basanez
SFSeth R Flaxman
Seth R Flaxman
JJJost B. Jonas
Jost B. Jonas
OSon behalf of the Vision Loss Expert Group of the Global Burden of Disease Study
on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study
Aim To estimate the magnitude, temporal trends and subregional variation in the prevalence of blindness, and moderate/severe vision impairment (MSVI) in sub-Saharan Africa. Methods A systematic review was conducted of published and unpublished population-based surveys as part of the Global Burden of Disease, Risk Factors and Injuries Study 2010. The prevalence of blindness and vision impairment by country and subregion was estimated. Results In sub-Saharan Africa, 52 studies satisfied the inclusion criteria. The estimated age-standardised prevalence of blindness decreased by 32% from 1.9% (95% CI 1.5% to 2.2%) in 1990 to 1.3% (95% CI 1.1% to 1.5%) in 2010 and MSVI by 25% from 5.3% (95% CI 0.2% to 0.3%) to 4.0% (95% CI 0.2% to 0.3%) over that time. However, there was a 16% increase in the absolute numbers with blindness and a 28% increase in those with MSVI. The major causes of blindness in 2010 were; cataract 35%, other/unidentified causes 33.1%, refractive error 13.2%, macular degeneration 6.3%, trachoma 5.2%, glaucoma 4.4% and diabetic retinopathy 2.8%. In 2010, age-standardised prevalence of MSVI in Africa was 3.8% (95% CI 3.1% to 4.7%) for men and 4.2% (95% CI 3.6% to 5.3%) for women with subregional variations from 4.1% (95% CI 3.3% to 5.4%) in West Africa to 2.0% (95% CI 1.5% to 3.3%) in southern Africa for men; and 4.7% (95% CI 3.9% to 6.0%) in West Africa to 2.3% (95% CI 1.7% to 3.8%) in southern Africa for women. Conclusions The age-standardised prevalence of blindness and MSVI decreased substantially from 1990 to 2010, although there was a moderate increase in the absolute numbers with blindness or MSVI. Significant subregional and gender disparities exist.

25 October 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JLJanet L. Leasher
Janet L. Leasher
RBRupert R.A. Bourne
Rupert R.A. Bourne
SFSeth R. Flaxman
Seth R. Flaxman
JJJost B. Jonas
Jost B. Jonas
JKJill Keeffe
Jill Keeffe
HTHugh R. Taylor
Hugh R. Taylor
In the article listed above, there is an error in Table 1. The value for “Number …

28 October 2025 in Ophthalmic and Physiological Optics
Verified
Journal Article
Open access
SMSara Jayne McCullough
Sara Jayne McCullough
HBHolly Barr
Holly Barr
JFJane Margaret Fulton
Jane Margaret Fulton
SJSusie Jones
Susie Jones
NLNicola Logan
Nicola Logan
NVNatalia Vlasak
Natalia Vlasak
Introduction: Myopia is a growing public health concern with long‐term risks for visual impairment. While Defocus Incorporated Multiple Segments (DIMS) spectacle lenses have proven efficacy in Chinese children, evidence from Western populations remains limited. This multi‐site interventional study evaluates the effectiveness of DIMS lenses in slowing myopia progression and their visual acceptability and tolerability among UK children. Methods: Children aged 5–15 years with cycloplegic spherical equivalent refraction (SER) of −0.50 to −8.50 D, anisometropia ≤1.50 D and astigmatism ≤2.50 D were recruited. All participants were prescribed DIMS spectacle lenses. SER (cycloplegic autorefraction) and axial length (AL, IOLMaster) were measured at baseline and at 6‐monthly intervals for 24 months. Measured axial elongation was compared to expected eye growth in age‐ and ethnicity‐matched untreated myopes from published meta‐analyses. Visual function (distance/near visual acuity, stereoacuity, accommodative lag and ocular posture) and visual symptoms (participant questionnaire) were also assessed. Results: A total of 108 participants completed the study to 2 years (baseline age 10.2 ± 2.2 years). Model‐adjusted mean (SE) changes in SER and AL change were −0.35 ± 0.04 D and 0.17 ± 0.01 mm at 12 months and −0.57 ± 0.05 D and 0.30 ± 0.03 mm at 24 months. Compared to expected untreated myopic progression, children wearing DIMS spectacle lenses showed 0.27 ± 0.20 mm (mean ± SD) less axial elongation over 24 months, with 91% exhibiting slower than average untreated myopic eye growth. Measures of visual function were comparable through DIMS and single‐vision spectacle lenses. Fifty‐seven percent of participants reported no visual symptoms within the first week, and on average, visual symptoms were ‘never’ or ‘seldom’ experienced by participants after 12 and 24 months of DIMS wear. Conclusions: This study provides robust and novel evidence demonstrating that DIMS spectacle lenses provide meaningful slowing of axial elongation among UK children. Minimal visual symptoms and preserved visual function throughout lens wear support their clinical viability and real‐world applicability for myopia management in diverse populations.